Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

114.15USD
20 Jan 2017
Change (% chg)

$-0.05 (-0.04%)
Prev Close
$114.20
Open
$114.49
Day's High
$115.03
Day's Low
$114.08
Volume
7,502,425
Avg. Vol
6,878,455
52-wk High
$126.07
52-wk Low
$94.28

Select another date:

Thu, Jan 19 2017

MDL Watch: Sanofi Taxotere, Bair Hugger and J&J talc cases grow

New multidistrict litigation over claims that a Sanofi breast cancer drug causes permanent hair loss more than doubled in size over the past month, and plaintiffs are continuing to mount ovarian cancer claims involving Johnson & Johnson's talc products in federal court.

BRIEF-Johnson & Johnson reports 7.4 pct stake in Merus NV as of Dec 31, 2016

* Johnson & Johnson reports 7.4 percent passive stake in Merus NV as of Dec 31, 2016 - SEC filing Source text: (http://bit.ly/2j9ZI8k) Further company coverage:

EU mergers and takeovers (Jan 18)

BRUSSELS, Jan 18 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

U.S. Supreme Court declines to hear J&J contact lens patent dispute

Johnson & Johnson will have to face a retrial of patent infringement claims over contact lens technology after the U.S. Supreme Court on Tuesday refused to review a lower court's decision overturning the company's win at an earlier trial.

11th Circuit asked to block former J&J executive's job with rival

Two Johnson & Johnson units have asked a U.S. appeals court to uphold a ruling that blocked a former longtime executive from taking a high-profile role at a rival medical device maker, saying her defection poses an imminent risk to the companies.

BRIEF-Orthocell announces collaboration with Johnson & Johnson

* Orthocell announces collaboration with Johnson & Johnson Innovation

J&J, Actelion approach Swiss takeover board over deal structure: paper

ZURICH Johnson & Johnson and Actelion have asked Switzerland's takeover board about the viability of a complicated takeover deal the U.S. healthcare company is discussing with the Swiss biotech firm, newspaper Tages-Anzeiger reported on Friday, without saying how it got the information.

J&J, Actelion approach Swiss takeover board over deal structure -paper

ZURICH, Jan 6 Johnson & Johnson and Actelion have asked Switzerland's takeover board about the viability of a complicated takeover deal the U.S. healthcare company is discussing with the Swiss biotech firm, newspaper Tages-Anzeiger reported on Friday, without saying how it got the information.

Judge halves $1 billion award in J&J hip implants case

A U.S. judge almost halved the award in a December jury verdict that ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay more than $1 billion to plaintiffs in six lawsuits who said they were injured by DePuy's Pinnacle hip implants.

Exclusive: J&J discussing breaking up Actelion in an acquisition - sources

Johnson & Johnson is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd that would separate its commercialized portfolio from its research and development assets, people familiar with the matter said on Thursday.

Select another date: